Fig. 6From: Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus studya Laboratory Monitoring and Testing. b Laboratory Monitoring and Testing (Hepatic or Renal Impairment). Statements with a consensus for are bolded; statements with consensus against are shown with a grey backgroundBack to article page